Mirati Therapeutics Inc

Market cap: $4,292,526,110

Exchange: NAS

Sector: Health Technology

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

STOCK PRICE CHART

Key Statistics

Company Name

Mirati Therapeutics Inc

Average Volume (10 days)

1,341,864

Average Volume (30 days)

990,003

Moving Average (50 days)

$67.7

Moving Average (200 days)

$67.59

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

-5.8163

Market Cap

4,292,526,110

Shares Outstanding

57,586,881

52-Week High Split Adjust Only

154.17

52-Week Low Split Adjust Only

32.96

Employee Count

200

Beta

1.1096

Next Earnings Date

2023-02-28

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

0.01%

Past 30 days

0.18%

Past 3 months

-0.04%

Past 6 months

0.18%

Past year

-0.46%

Past 2 years

-0.67%

Past 5 years

3.37%

Max % Change

23.71%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
Mirati Therapeutics IncMRTX619.546.46-15.1619.54521.52
Peer AvgN/An/a-2086.9812.3n/an/a
TravelCenters of America IncTAn/an/a61.7n/an/a
Nymox Pharmaceutical CorpNYMXn/a-10434.91n/an/an/a